Vaccitech

Vaccitech Limited is a biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, such as hepatitis B, HPV and prostate cancer.[1][2]

Vaccitech Limited
IndustryVaccines
Immunotherapy
Biotechnology
Founded2016 (2016)
Founder
Headquarters
Oxford Science Park, Oxford
,
United Kingdom
Websitevaccitech.co.uk

Technology

The company's platform includes Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two viral vectors which mimic viral disease in human cells and elicit antibody and T cell responses to pathogens and tumours.[3]

History

The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at the Jenner Institute, University of Oxford.[4][5][6][7]

Vaccitech has been financed and supported by Google Ventures (GV), Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).[8] As of 2020 investment in vaccitech has included over £20m of series A round funding.[7]

In early 2020, Vaccitech and the University of Oxford co-invented a vaccine for COVID-19 using the ChAdOx platform. Phase 3 clinical trials for the vaccine are ongoing, conducted by the University and development partners, AstraZeneca.

COVID-19 vaccine

In July 2020, it was reported that people in Brazil, South Africa and the US had been recruited to populate the vaccine trials.[9]

In July 2020, Vaccitech scientists reported in The Lancet a "single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein." Several subjects needed prophylactic paracetamol to minimize their adverse reactions. The results seemed to "support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme."[10]

References
  1. Vaccitech on Twitter
  2. Anon (2016). "Vaccitech Limited". companieshouse.gov.uk. London: Companies House.
  3. Anon (2019). "Vaccitech - Creating ways to treat and prevent disease". vaccitech.co.uk. Vaccitech Limited.
  4. Anon (2020). "Company listing". crunchbase.com. Crunchbase. Retrieved 2020-04-24.
  5. Anon (2019). "Vaccitech Ltd". bloomberg.com. Bloomberg News.
  6. Anon (2016). "Universal flu vaccine under development by Oxford spinout Vaccitech". ox.ac.uk. University of Oxford.
  7. Anon (2019). "Vaccitech secures £20m Series A with GV, OSI and Sequoia China". innovation.ox.ac.uk. Oxford University Innovation.
  8. Anon (2019). "About Vaccitech". vaccitech.co.uk. Vaccitech Limited.
  9. Boseley, Sarah (1 July 2020). "Oxford offers best hope for Covid-19 vaccine this year, MPs told". Guardian News & Media Limited.
  10. Folegatti, Pedro M.; Ewer, Katie J.; Aley, Parvinder K.; Angus, Brian; Becker, Stephan; Belij-Rammerstorfer, Sandra; Bellamy, Duncan; Bibi, Sagida; Bittaye, Mustapha; Clutterbuck, Elizabeth A.; Dold, Christina; Faust, Saul N.; Finn, Adam; Flaxman, Amy L.; Hallis, Bassam; Heath, Paul; Jenkin, Daniel; Lazarus, Rajeka; Makinson, Rebecca; Minassian, Angela M.; Pollock, Katrina M.; Ramasamy, Maheshi; Robinson, Hannah; Snape, Matthew; Tarrant, Richard; Voysey, Merryn; Green, Catherine; Douglas, Alexander D.; Hill, Adrian V S.; et al. (2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial". The Lancet. 396 (10249): 467–478. doi:10.1016/S0140-6736(20)31604-4. PMC 7445431. PMID 32702298.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.